CN1314909A - 具有抗HIV活性的d4T的磷酸芳基酯衍生物 - Google Patents
具有抗HIV活性的d4T的磷酸芳基酯衍生物 Download PDFInfo
- Publication number
- CN1314909A CN1314909A CN99810072A CN99810072A CN1314909A CN 1314909 A CN1314909 A CN 1314909A CN 99810072 A CN99810072 A CN 99810072A CN 99810072 A CN99810072 A CN 99810072A CN 1314909 A CN1314909 A CN 1314909A
- Authority
- CN
- China
- Prior art keywords
- compound
- composition
- hiv
- group
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/107,716 US6030957A (en) | 1998-06-29 | 1998-06-29 | Aryl phosphate derivatives of d4T having anti-HIV activity |
| US09/107716 | 1998-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1314909A true CN1314909A (zh) | 2001-09-26 |
Family
ID=22318071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN99810072A Pending CN1314909A (zh) | 1998-06-29 | 1999-06-29 | 具有抗HIV活性的d4T的磷酸芳基酯衍生物 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US6030957A (enExample) |
| EP (1) | EP1090018B1 (enExample) |
| JP (1) | JP2002519355A (enExample) |
| KR (1) | KR20010071673A (enExample) |
| CN (1) | CN1314909A (enExample) |
| AT (1) | ATE277940T1 (enExample) |
| AU (1) | AU4846999A (enExample) |
| BR (1) | BR9911685A (enExample) |
| CA (1) | CA2336285A1 (enExample) |
| DE (1) | DE69920696T2 (enExample) |
| HU (1) | HUP0102527A3 (enExample) |
| IL (1) | IL140388A0 (enExample) |
| NO (1) | NO20006685L (enExample) |
| WO (1) | WO2000000501A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103403014A (zh) * | 2011-01-03 | 2013-11-20 | 南京迈勒克生物技术研究中心 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030957A (en) * | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
| US20070015733A1 (en) * | 1998-06-29 | 2007-01-18 | Parker Hughes Institute | Aryl Phosphate Derivatives of d4T having Activity Against Resistant HIV Strains |
| US7144874B2 (en) * | 2002-10-25 | 2006-12-05 | Parker Hughes Institute | Aryl phosphate derivatives of d4T having activity against resistant HIV strains |
| WO2000056750A1 (en) * | 1999-03-19 | 2000-09-28 | Parker Hughes Institute | One pot synthesis of 5'-hydroxy phosphorylated nucleoside derivatives, and compounds formed thereby |
| US6825177B2 (en) * | 2000-10-30 | 2004-11-30 | Parker Hughes Institute | Aryl phosphate derivatives of d4T with potent anti-viral activity |
| ATE297940T1 (de) * | 2000-11-13 | 2005-07-15 | Parker Hughes Inst | Arylphosphatderivate von d4t |
| AU2003239901A1 (en) * | 2002-05-28 | 2003-12-12 | Kathy M. Ensrud | Crisp polypeptides as contraceptives and inhibitors of sperm capacitation |
| US20030236218A1 (en) * | 2002-06-12 | 2003-12-25 | Uckun Fatih M. | Aryl phosphate derivatives of d4T with selective activity against adenovirus and HIV |
| US20040076931A1 (en) * | 2002-10-18 | 2004-04-22 | Cashflow Technologies, Inc. | Educational interactive games |
| US20040077607A1 (en) * | 2002-10-21 | 2004-04-22 | Uckun Fatih M. | Aryl phosphate derivatives of d4T with potent anti-viral activity against hemorrhagic fever viruses |
| GB0401088D0 (en) | 2004-01-19 | 2004-02-18 | Univ Cardiff | Phosphoramidate derivatives |
| EP1773355B1 (en) * | 2004-06-24 | 2014-06-25 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
| WO2006026656A1 (en) * | 2004-08-31 | 2006-03-09 | Parker Hughes Institute | Cytotoxic nucleoside analog compound 003 for treating cancer |
| EP1827460A4 (en) * | 2004-12-09 | 2012-03-14 | Univ Minnesota | NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT |
| US10618013B2 (en) * | 2005-03-09 | 2020-04-14 | The Regents Of The University Of California | Nanocomposite membranes and methods of making and using same |
| US7892618B2 (en) * | 2005-03-21 | 2011-02-22 | Sony Corporation | Deterring theft of optical media |
| GB0623493D0 (en) * | 2006-11-24 | 2007-01-03 | Univ Cardiff | Chemical compounds |
| EP2623104A1 (en) * | 2009-03-20 | 2013-08-07 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
| CA2810928A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| CA2860234A1 (en) | 2011-12-22 | 2013-06-27 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
| HK1206362A1 (zh) | 2012-03-21 | 2016-01-08 | Alios Biopharma, Inc. | 硫代氨基磷酸酯核苷酸前藥的固體形式 |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| CN105705511A (zh) | 2013-04-12 | 2016-06-22 | 艾其林医药公司 | 用于治疗hcv的氘化核苷前药 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707362A (en) | 1985-02-15 | 1987-11-17 | Biotek, Inc. | Sustained release composition |
| US4841039A (en) | 1986-05-01 | 1989-06-20 | Emory University | 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents |
| US4983393A (en) | 1987-07-21 | 1991-01-08 | Maximed Corporation | Intra-vaginal device and method for sustained drug release |
| JPH06189998A (ja) | 1992-11-06 | 1994-07-12 | C & Co:Yugen | コンド―ム |
| CA2130265A1 (en) | 1992-12-18 | 1994-07-07 | Edward E. Knaus | Dihydropyrimidine nucleosides with antiviral properties |
| ZA947572B (en) | 1993-09-29 | 1995-09-28 | Hampton Roads Medical College | Contraceptive compositions |
| US5672698A (en) * | 1993-11-15 | 1997-09-30 | Bristol-Myers Squibb Co. | Preparation of 2',3'-didehydro-3'-deoxythymidine from 5-methyluridine |
| US5659023A (en) * | 1995-02-01 | 1997-08-19 | Gilead Sciences, Inc. | Nucleotide analogues |
| GB9505025D0 (en) * | 1995-03-13 | 1995-05-03 | Medical Res Council | Chemical compounds |
| IL126804A0 (en) | 1996-05-09 | 1999-08-17 | Bergeron Michel G | Formulation for use in the prevention of pathogen induced diseases including hiv and hsv |
| US6030957A (en) | 1998-06-29 | 2000-02-29 | Wayne Hughes Institute | Aryl phosphate derivatives of d4T having anti-HIV activity |
-
1998
- 1998-06-29 US US09/107,716 patent/US6030957A/en not_active Expired - Fee Related
-
1999
- 1999-06-29 CA CA002336285A patent/CA2336285A1/en not_active Abandoned
- 1999-06-29 AT AT99932080T patent/ATE277940T1/de not_active IP Right Cessation
- 1999-06-29 EP EP99932080A patent/EP1090018B1/en not_active Expired - Lifetime
- 1999-06-29 WO PCT/US1999/014774 patent/WO2000000501A1/en not_active Ceased
- 1999-06-29 DE DE69920696T patent/DE69920696T2/de not_active Expired - Fee Related
- 1999-06-29 HU HU0102527A patent/HUP0102527A3/hu unknown
- 1999-06-29 AU AU48469/99A patent/AU4846999A/en not_active Abandoned
- 1999-06-29 IL IL14038899A patent/IL140388A0/xx unknown
- 1999-06-29 KR KR1020007014949A patent/KR20010071673A/ko not_active Withdrawn
- 1999-06-29 BR BR9911685-5A patent/BR9911685A/pt not_active Application Discontinuation
- 1999-06-29 JP JP2000557262A patent/JP2002519355A/ja active Pending
- 1999-06-29 CN CN99810072A patent/CN1314909A/zh active Pending
- 1999-11-29 US US09/450,082 patent/US6503890B1/en not_active Expired - Fee Related
- 1999-12-15 US US09/464,516 patent/US6350736B1/en not_active Expired - Fee Related
-
2000
- 2000-04-13 US US09/548,492 patent/US6528495B1/en not_active Expired - Fee Related
- 2000-04-13 US US09/548,494 patent/US6670336B1/en not_active Expired - Fee Related
- 2000-04-13 US US09/548,496 patent/US6537975B1/en not_active Expired - Fee Related
- 2000-12-28 NO NO20006685A patent/NO20006685L/no not_active Application Discontinuation
-
2003
- 2003-12-01 US US10/726,073 patent/US7071176B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103403014A (zh) * | 2011-01-03 | 2013-11-20 | 南京迈勒克生物技术研究中心 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
| CN103403014B (zh) * | 2011-01-03 | 2016-07-06 | 河南美泰宝生物制药有限公司 | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0102527A3 (en) | 2002-04-29 |
| US6030957A (en) | 2000-02-29 |
| AU4846999A (en) | 2000-01-17 |
| EP1090018A1 (en) | 2001-04-11 |
| BR9911685A (pt) | 2001-12-18 |
| ATE277940T1 (de) | 2004-10-15 |
| US6350736B1 (en) | 2002-02-26 |
| EP1090018B1 (en) | 2004-09-29 |
| US7071176B2 (en) | 2006-07-04 |
| HUP0102527A2 (hu) | 2001-12-28 |
| JP2002519355A (ja) | 2002-07-02 |
| US6503890B1 (en) | 2003-01-07 |
| NO20006685D0 (no) | 2000-12-28 |
| DE69920696D1 (de) | 2004-11-04 |
| NO20006685L (no) | 2001-02-28 |
| KR20010071673A (ko) | 2001-07-31 |
| US6528495B1 (en) | 2003-03-04 |
| CA2336285A1 (en) | 2000-01-06 |
| US6670336B1 (en) | 2003-12-30 |
| WO2000000501A1 (en) | 2000-01-06 |
| IL140388A0 (en) | 2002-02-10 |
| US6537975B1 (en) | 2003-03-25 |
| US20040171577A1 (en) | 2004-09-02 |
| DE69920696T2 (de) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1314909A (zh) | 具有抗HIV活性的d4T的磷酸芳基酯衍生物 | |
| CN100343268C (zh) | β-2′-或3′-卤代核苷 | |
| CN103403014B (zh) | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 | |
| Nair et al. | Antiviral activities of isometric dideoxynucleosides of D-and L-related stereochemistry | |
| US8895531B2 (en) | 2′-fluoronucleoside phosphonates as antiviral agents | |
| McIntee et al. | Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs | |
| US20140212382A1 (en) | Purine monophosphate prodrugs for treatment of viral infections | |
| JP2005503358A5 (enExample) | ||
| WO2017197377A1 (en) | Peptidomimetics for the treatment of norovirus infection | |
| JPH0780898B2 (ja) | 抗ウイルスヌクレオシド | |
| WO2003051306A2 (en) | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | |
| Zhou et al. | 2′-Chloro, 2′-fluoro ribonucleotide prodrugs with potent pan-genotypic activity against hepatitis C virus replication in culture | |
| Meier et al. | C yclo Sal-BVDUMP Pronucleotides: How to Convert an Antiviral-Inactive Nucleoside Analogue into a Bioactive Compound against EBV | |
| Krecmerova et al. | Synthesis of ester prodrugs of 9-(S)-[3-hydroxy-2-(phosphonomethoxy) propyl]-2, 6-diaminopurine (HPMPDAP) as anti-poxvirus agents | |
| Kim et al. | Synthesis and anti-hepatitis B virus and anti-hepatitis C virus activities of 7-deazaneplanocin A analogues in vitro | |
| WO2006017052A1 (en) | Process for the preparation of a1 adenosine receptor agonists | |
| US11618765B2 (en) | Broad-spectrum antiviral nucleoside derivatives | |
| Koszalka et al. | Advances in Nucleoside and Nucleotide Antiviral Therapies | |
| Bryant et al. | Antiviral β-L-nucleosides specific for hepatitis B virus infection | |
| Ducho et al. | Novel cycloSal nucleotides with reduced inhibitory potency toward human butyrylcholinesterase | |
| HK1195317A (en) | Purine monophosphate prodrugs for treatment of viral infections | |
| HK1076473B (en) | β-2'-OR 3'-HALONUCLEOSIDES | |
| MXPA00013013A (en) | ARYL PHOSPHATE DERIVATIVES OF d4T HAVING ANTI-HIV ACTIVITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| C10 | Entry into substantive examination | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |